PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA)

Breast Cancer Clinical Trial

— PALMIRA  

Official title:

International,Multicenter,Randomized,Open-label, Phase II to Evaluate the Efficacy and Safety of Continuation of Palbociclib+2nd Line Endocrine Therapy in HR+/HER2- ABC Patients Who Had Clinical Benefit During 1st Line Palbociclib.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03809988
• Other study ID #: MedOPP068
• Secondary ID: 2017-002781-48
• Status: Completed
• Phase: Phase 2
• Start date: April 5, 2019
• Est. completion date: November 30, 2022

Study information

• Verified date: September 2023
• Source: MedSIR
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Hormone Receptor (HR)-positive/Human Epidermal Growth Factor Receptor 2 (HER2)-negative advanced breast cancer (ABC)

Description:

Pre- and post-menopausal women age ≥ 18 years with HR-positive and HER2-negative with ABC that had previously received first-line endocrine therapy in combination with palbociclib and had achieved clinical benefit during palbociclib-based treatment. Patients relapsing on a palbociclib-based regimen in the adjuvant setting are also eligible. Patients are not eligible if they are candidates for a local treatment with a curative intention. Evidence of either measurable and biopsiable metastatic disease (as for Response Evaluation Criteria In Solid Tumors (RECIST v.1.1)) or non-measurable disease with bone lesion is required. Pre-menopausal women must be under treatment with luteinizing hormone-releasing hormone (LHRH) analogues.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 198
• Est. completion date: November 30, 2022
• Est. primary completion date: November 30, 2022
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Female patients over 18 years of age.

2. Pre-menopausal women provided they are being treated with a LHRH analogue for at least 28 days (if shorter, post-menopausal levels of serum estradiol/Follicle-stimulating hormone (FSH) must be confirmed analytically) prior to study entry or post- menopausal

women as defined by any of the following criteria:

1. Age =60 years;

2. Age <60 years and cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause; and serum estradiol and/or FSH level within the laboratory's reference range for postmenopausal females;

3. Documented bilateral oophorectomy.

3. Eastern Cooperative Oncology Group (ECOG) performance status lower or equal to 1.

4. Life expectancy greater or equal to 12 weeks.

5. Histologically proven diagnosed of ABC not amenable to curative treatment.

6. Documented recurrent ER-positive and/or progesterone receptor (PgR)-positive (with =1% positive stained cells (according to NCCN National Comprehensive Cancer Network and ASCO American Society of Clinical Oncology guidelines) and HER2-negative (0-1+ by immunohistochemistry (IHC) or 2+ and negative by in situ hybridization (ISH) test) breast cancer in the advanced setting.

7. Radiological or clinical evidence of disease progression on first- line combination of palbociclib plus endocrine therapy (aromatase inhibitor (AI) or fulvestrant). Patients previously treated with the combination of palbociclib and tamoxifen will be excluded.

8. Patients have achieved clinical benefit criteria to a first-line palbociclib-based endocrine regimen (defined as at least stable disease = 24 weeks or partial or complete response confirmed or unconfirmed).

9. Patients must have been treated with a stable minimum dose of 75 mg palbociclib during the last 2 cycles of the prior palbociclib-based regimen.

10. Last dose of palbociclib administered not later than 8 weeks and not earlier than 7 days from study entry, with the exception of patients relapsing on a palbociclib-based regimen in the adjuvant setting.

11. Patients should not have been treated in the advanced setting with at least one of these endocrine therapy options: either fulvestrant or AI.

12. Patients must have measurable disease or evaluable disease according to RECIST criteria v.1.1. Patients with only bone lesions are eligible.

13. Willingness and ability to provide tumor biopsy (if feasible) both at the time of the inclusion and after disease progression in order to perform exploratory studies. If not feasible, patient eligibility should be evaluated by a Sponsor's qualified designee.

14. Patients agree to collection of blood samples (liquid biopsy) at the time of inclusion, after 2 weeks of treatment, and upon progression or study termination.

15. Adequate organ function: (Hematological, hepatic and renal)

16. Patients who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

17. Patients have been informed about the nature of study, and have agreed to participate in the study, and signed the informed consent form prior to participation in any study-related activities.

18. Resolution of all acute toxic effects of prior anti-cancer therapy to grade 1

Exclusion Criteria:

1. HR or HER2 unknown disease.

2. HER2-positive disease based on local laboratory results (performed by IHC / ISH test).

3. Locally ABC candidate for curative treatment.

4. Formal contraindication to endocrine therapy defined as visceral crisis and rapidly or symptomatic progressive visceral disease.

5. Prior therapy with any other CDK4/6 inhibitor different from palbociclib.

6. Known active uncontrolled or symptomatic Central Nervous System (CNS) metastases, carcinomatous meningitis, or leptomeningeal disease as indicated by clinical symptoms, cerebral edema, and/or progressive growth. Patients with a history of CNS metastases or cord compression are eligible if they have been definitively treated and are clinically stable off anticonvulsants and steroids for at least 4 weeks before randomization.

7. Patients are currently receiving food or drugs known to be strong inducers or inhibitors of CYP3A4.

8. Current or prior malignancy which could affect compliance with the protocol or interpretation of results. Patients with curatively- treated non-melanoma skin cancer, non-muscle-invasive bladder cancer, or carcinoma in situ, among others, are generally eligible.

9. No other systemic therapy for metastatic disease including chemotherapy, immunotherapy, targeted therapy (small molecules/ monoclonal antibodies), or endocrine therapy excluding first-line palbociclib-based regimen.

10. Major surgery (defined as requiring general anesthesia) or significant traumatic injury within 2 weeks of start of study drug, or patients who have not recovered from the side effects of any major surgery, or patients who may require major surgery during the study.

11. Radiotherapy or limited-field palliative radiotherapy within 7 days prior to study enrolment, or patients who have not recovered from radiotherapy-related toxicities to baseline or grade = 1 and/or from whom = 25% of the bone marrow has been previously irradiated.

12. Use of concurrent investigational agents or other concomitant anticancer therapies.

13. Active bleeding diathesis, previous history of bleeding diathesis, or chronic anti-coagulation treatment (the use of low molecular weight heparin is allowed as soon as it is used as prophylaxis intention).

14. Serious concomitant systemic disorder (e.g., active infection including HIV, or cardiac disease) incompatible with the study (at the discretion of investigator).

15. Unable to swallow capsules or tablets.

16. History of malabsorption syndrome or other condition that would interfere with enteral absorption.

17. Any of the following within 6 months of randomization:

myocardial infarction, severe/unstable angina, ongoing cardiac dysrhythmias of NCI-CTCAE v.5.0 grade =2, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident including transient ischemic attack, or symptomatic pulmonary embolism.

18. Uncontrolled electrolyte disorders of NCI-CTCAE v.5.0 grade = 2.

19. Known hypersensitivity to palbociclib or any of its excipients.

Related Conditions & MeSH terms

• Advanced Breast Cancer
• Breast Cancer
• Breast Neoplasms
• Hormone Receptor Positive Tumor
• Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

Intervention

Drug:
• Palbociclib
Palbociclib capsules orally once daily (QD) (at 100mg or 125mg depending on previous treatment dose) for 21 days every four weeks
• Endocrine therapy
Endocrine therapy alone (letrozole or fulvestrant)

Locations

Country	Name	City	State
France	Hôpital Jean Minjoz	Besançon
France	Polyclinique Bordeaux Nord Aquitaine	Bordeaux
France	Centre Georges François Leclerc	Dijon
France	CHD Vendee	La Roche-sur-Yon
France	Hopital Europeen Georges Pompidou	Paris
France	Hôpital Tenon AP-HP	Paris
France	Centre Paul Strauss	Strasbourg
Germany	University Hospital Dresden-GYN	Dresden
Germany	Kliniken Essen Mitte	Essen
Germany	Universitätsklinikum Essen Frauenklinik	Essen
Germany	AGAPLESION Markus Krankenhaus	Frankfurt
Germany	Technical University Munich	Munich
Germany	UKM Brustzentrum	Münster
Germany	Klinikum Ernst von Bergmann	Potsdam
Germany	Klinikum Mutterhaus der Borromäerinnen Trier	Trier
Italy	Ospedale Civili Brescia	Brescia
Italy	Instituto Europeo di Oncologia	Milano
Italy	Oncologia Medica Ospedale di Prato	Prato
Italy	Policlinico Universitario Campus Bio-medico	Roma
Slovenia	Onkološki Inštitut Ljubljana	Ljubljana
Slovenia	Univerzitetni klinicni center Maribor Oddelek za onkologijo	Maribor
Spain	Centro Oncológico de Galicia	A Coruña
Spain	ICO Badalona	Badalona	Barcelona
Spain	H. Vall Hebrón	Barcelona
Spain	Hospital del Mar	Barcelona
Spain	Institut Català d'Oncologia Bellvitge	Barcelona
Spain	Hospital de Basurto	Bilbao
Spain	Hospital San Pedro de Alcantara	Cáceres
Spain	Hospital Provincial de Castellón	Castello	Castelló
Spain	Institut Català d'Oncologia	Girona
Spain	Hospital Arnau de Vilanova	Lleida
Spain	Hospital Clinico San Carlos	Madrid
Spain	Hospital La Paz	Madrid
Spain	Hospital Universitario Sanchinarro	Madrid
Spain	Hospital Regional Universitario de Malaga	Málaga
Spain	Hospital Universitari Son Espases	Palma De Mallorca
Spain	Hospital Sant Joan	Reus
Spain	Hospital Universitario Virgen de la Macarena	Sevilla
Spain	Hospital Universitario Virgen del Rocío	Sevilla
Spain	Consorci Sanitari de Terrassa	Terrassa	Terrasa
Spain	Hospital Arnau de Vilanova de Valencia	Valencia
Spain	Hospital General Universitari de Valencia	Valencia
Spain	Hospital Universitari i Politecnic La Fe	Valencia
Spain	Instituto Valenciano de Oncología IVO	Valencia
Spain	Hospital Álvaro Cunqueiro	Vigo
Spain	Hospital Lozano Blesa	Zaragoza
Spain	Hospital Miguel Servet	Zaragoza
United Kingdom	Darent Valley Hospital by Dartford and Gravesham NHS Trust	Dartford
United Kingdom	Beatson West of Scotland Cancer Center	Glasgow
United Kingdom	Barts Cancer Institute	London
United Kingdom	Kent Oncology Department	Maidstone
United Kingdom	Abertawe Bro Morgannwg University Local Health Board, Singleton Hospital	Swansea
United Kingdom	Royal Cornwall Hospital NHS Trust	Truro

Sponsors (2)

Lead Sponsor	Collaborator
MedSIR	Pfizer

Countries where clinical trial is conducted

France,  Germany,  Italy,  Slovenia,  Spain,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	PFS (Progression-free survival)	From a clinical point of view, the primary endpoint for this study is the PFS (progression-free survival) - defined as the period of time from randomization until objective tumor progression or death - assessed by RECIST criteria v.1.1, of continuation of palbociclib treatment combined with second-line endocrine therapy (letrozole or fulvestrant) versus endocrine therapy in pre- and post- menopausal women with HR-positive/HER2-negative ABC.	Baseline up to 29 months
Secondary	Safety AEs	Patient safety and adverse events (AEs) will be evaluated using the NCI-CTCAE v.5.0. Grade 3 and 4 AEs and serious adverse events (SAEs) will be assessed to determine the safety and tolerability of the different treatment arms.	Baseline up to 29 months
Secondary	Efficacy (ORR)	To compare the objective response rate (ORR), the duration of response (DoR), the time to response (TTR), the clinical benefit rate (CBR), the time to progression (TTP), and the overall survival (OS) of palbociclib plus second-line endocrine therapy (letrozole or fulvestrant) versus endocrine therapy alone	Baseline up to 29 months
Secondary	Efficacy (Quality of Life)	To compare the patient reported global Quality of Life (QOL), functioning and symptoms of palbociclib plus second-line endocrine therapy (letrozole or fulvestrant) versus endocrine therapy alone.	Baseline up to 42 months
Secondary	Efficacy of subgroup analysis	To perform subgroup analysis for primary and secondary endpoints in stratified groups of patients.	Baseline up to 42 months
Secondary	Compare efficacy	To compare the time to first chemotherapy of palbociclib plus second-line endocrine therapy (letrozole or fulvestrant) versus endocrine therapy alone.	Baseline up to 42 months
Secondary	Exploratory objectives (molecular markers)	To explore potential molecular markers of sensitivity and/or resistance for the combination and endocrine therapy alone, according to, but not limited to, the results obtained from the BioPER trial (NCT03184090).	Baseline up to 42 months
Secondary	Exploratory objectives (intrinsic molecular subtypes)	To explore correlations between the intrinsic molecular subtypes and efficacy/safety findings in patients with HR-positive/HER2- negative ABC.	Baseline up to 42 months